Primus In News
Indian pharma ramps up US acquisitions amid regulatory and market shifts
15-03-2025
Nilaya Varma, CEO & Co-Founder, Primus Partners, and Vivek Tandon, Vice President, Primus Partners, share their view on the expansion of Indian pharmaceutical companies in the US through strategic acquisitions. They highlight Sun Pharma’s $355 million acquisition of Checkpoint Therapeutics as a key move to bolster its oncology and immunotherapy portfolio.
Explore Related Insights
- Budget 2025: Agri industry calls for policy reforms to boost sustainability and rural growth
- Indian online gaming industry with considerable growth potential, regulatory changes cause concerns: Report
- Airport lounge access through cards getting tougher: Factors you must know to avoid last-minute shock
- Luxe automakers on top gear to woo buyers in upscale lounge ambience
